NO20052310L - Posisjonsisomerer av PEG IFN alfa 2A. - Google Patents

Posisjonsisomerer av PEG IFN alfa 2A.

Info

Publication number
NO20052310L
NO20052310L NO20052310A NO20052310A NO20052310L NO 20052310 L NO20052310 L NO 20052310L NO 20052310 A NO20052310 A NO 20052310A NO 20052310 A NO20052310 A NO 20052310A NO 20052310 L NO20052310 L NO 20052310L
Authority
NO
Norway
Prior art keywords
position isomers
peg ifn
ifn alfa
alfa
treatment
Prior art date
Application number
NO20052310A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052310D0 (no
Inventor
Doris Brugger
Stefan Foser
Alfred Schacher
Karl Weyer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20052310D0 publication Critical patent/NO20052310D0/no
Publication of NO20052310L publication Critical patent/NO20052310L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20052310A 2002-11-15 2005-05-11 Posisjonsisomerer av PEG IFN alfa 2A. NO20052310L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02025585 2002-11-15
PCT/EP2003/012498 WO2004045648A1 (en) 2002-11-15 2003-11-10 Positional isomers of peg ifn alpha 2a

Publications (2)

Publication Number Publication Date
NO20052310D0 NO20052310D0 (no) 2005-05-11
NO20052310L true NO20052310L (no) 2005-08-09

Family

ID=32319537

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052310A NO20052310L (no) 2002-11-15 2005-05-11 Posisjonsisomerer av PEG IFN alfa 2A.

Country Status (23)

Country Link
US (1) US20040223950A1 (pl)
EP (1) EP1562634B1 (pl)
JP (1) JP4279258B2 (pl)
KR (1) KR20050065677A (pl)
CN (1) CN1323722C (pl)
AR (1) AR042039A1 (pl)
AT (1) ATE337017T1 (pl)
AU (1) AU2003293668A1 (pl)
BR (1) BR0316227A (pl)
CA (1) CA2503594C (pl)
DE (1) DE60307881T2 (pl)
ES (1) ES2270152T3 (pl)
GT (1) GT200300244A (pl)
MX (1) MXPA05005178A (pl)
NO (1) NO20052310L (pl)
PA (1) PA8587801A1 (pl)
PE (1) PE20040834A1 (pl)
PL (1) PL376883A1 (pl)
RU (1) RU2005118752A (pl)
TW (1) TW200413404A (pl)
UY (1) UY28080A1 (pl)
WO (1) WO2004045648A1 (pl)
ZA (1) ZA200503756B (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1565205A4 (en) * 2002-11-18 2006-07-05 Maxygen Inc Interferon-alpha polypeptides and conjugates
BRPI0507169A (pt) 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
AU2008201682B2 (en) * 2004-02-02 2011-02-24 Ambrx, Inc. Modified human interferon polypeptides and their uses
CN101115769A (zh) 2004-05-19 2008-01-30 马克西根公司 干扰素-α多肽和偶联物
EP1888633A4 (en) 2005-05-18 2010-01-27 Maxygen Inc UNFOLDED INTERFERON ALPHA POLYPEPTIDE
CA2612901A1 (en) * 2005-06-20 2007-01-04 Pepgen Corporation Low-toxicity, long-circulating chimeras of human interferon- alpha analogs and interferon tau
US7695710B2 (en) 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN101002944B (zh) * 2006-01-17 2012-07-25 中国科学院过程工程研究所 支链聚乙二醇-干扰素结合物及其制备方法
AR078117A1 (es) * 2006-06-20 2011-10-19 Protech Pharma S A Una muteina recombinante del interferon alfa humano glicosilado, un gen que codifica para dicha muteina, un metodo de produccion de dicho gen, un metodo para obtener una celula eucariota productora de dicha muteina, un metodo para producir dicha muteina, un procedimiento para purificar dicha muteina
KR101483814B1 (ko) * 2007-09-04 2015-01-16 바이오스티드 진 익스프레션 테크. 컴파니 리미티드 폴리에틸렌 글리콜에 의해 변형된 인터페론 알파 2ａ, 이의 합성 방법 및 용도
AU2007358605B8 (en) * 2007-09-04 2012-02-02 Biosteed Gene Expression Tech. Co., Ltd. Polyethylene glycol modified interferon alpha 2b and preparation method and applications thereof
US9840546B2 (en) * 2008-04-03 2017-12-12 Biosteed Gene Expression Tech. Co., Ltd. Double-stranded polyethylene glycol modified growth hormone, preparation method and application thereof
EP2113256A1 (en) 2008-04-29 2009-11-04 Ascendis Pharma AS PEGylated rhGH compounds
MX344559B (es) 2008-04-29 2016-12-20 Ascendis Pharma As Compuestos de hormona de crecimiento humana recombinante unidos al peg.
DE102009009344B4 (de) * 2009-02-05 2018-01-04 Helmholtz-Zentrum Dresden - Rossendorf E.V. Verfahren und Anordnung zur Reinigung des Reaktionsgemisches bei der Herstellung von Radiopharmaka
WO2010110503A1 (ko) * 2009-03-27 2010-09-30 주식회사 중외제약 인터페론-알파 및 세포질 잔류성 세포막 투과 펩타이드를 포함하는 IFN-α 융합 단백질
CN101514229B (zh) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物
MX337432B (es) 2009-12-15 2016-03-04 Ascendis Pharma As Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero.
SG11201703870UA (en) 2014-11-18 2017-06-29 Ascendis Pharma Endocrinology Div As Novel polymeric hgh prodrugs
PT3220892T (pt) 2014-11-21 2021-11-05 Ascendis Pharma Endocrinology Div A/S Formas de dosagem de hormona do crescimento de longa ação
CN106749608B (zh) * 2015-11-18 2021-10-15 石药集团中奇制药技术（石家庄）有限公司 干扰素α缀合物
AU2020233198B2 (en) 2019-03-04 2025-05-15 Ascendis Pharma Endocrinology Division A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
MXPA05002476A (es) * 2002-09-05 2005-10-19 Gi Company Inc Asialo-interferones modificados y sus usos.

Also Published As

Publication number Publication date
GT200300244A (es) 2004-06-03
EP1562634A1 (en) 2005-08-17
KR20050065677A (ko) 2005-06-29
WO2004045648A1 (en) 2004-06-03
JP4279258B2 (ja) 2009-06-17
CA2503594A1 (en) 2004-06-03
CN1323722C (zh) 2007-07-04
ES2270152T3 (es) 2007-04-01
PE20040834A1 (es) 2004-11-17
AR042039A1 (es) 2005-06-08
RU2005118752A (ru) 2006-02-10
CA2503594C (en) 2011-05-10
DE60307881T2 (de) 2007-03-08
CN1711109A (zh) 2005-12-21
PA8587801A1 (es) 2004-09-16
EP1562634B1 (en) 2006-08-23
BR0316227A (pt) 2005-10-04
DE60307881D1 (de) 2006-10-05
ZA200503756B (en) 2008-02-27
TW200413404A (en) 2004-08-01
JP2006515571A (ja) 2006-06-01
NO20052310D0 (no) 2005-05-11
US20040223950A1 (en) 2004-11-11
PL376883A1 (pl) 2006-01-09
AU2003293668A1 (en) 2004-06-15
ATE337017T1 (de) 2006-09-15
UY28080A1 (es) 2004-05-31
MXPA05005178A (es) 2005-07-22

Similar Documents

Publication Publication Date Title
NO20052310L (no) Posisjonsisomerer av PEG IFN alfa 2A.
DE60311272D1 (de) Neue purin- oder pyrrolol(2,3-d)pyrimidin-2-carbonsäurenitrile zur behandlung von mit cysteinproteaseaktivität assoziierten krankheiten
BRPI0411900B8 (pt) compostos e composições farmacêuticas compreendendo os mesmos
MY144616A (en) Substituted dihydroquinazolines
DOP2002000429A (es) Imidazotriazinas
NO20053077D0 (no) Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer.
WO2004014312A3 (en) Small-mer compositions and methods of use
BR122020006906B8 (pt) compostos e composições farmacêuticas antivirais
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
EP1495141A4 (en) THERAPY OF HIV
IS7814A (is) Fenetanólamín afleiða í meðhöndlun á öndunarfærasjúkdómum.
BRPI0416936A (pt) sistemas de anel de imidazo substituìdos e métodos
ATE453642T1 (de) Substituierte phenylaminopyrimidine
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
NO20033123D0 (no) Terapeutisk hinnedannende sammensetning og behandlingsplan derav
UY28313A1 (es) Nonadepsipeptidos acilados
DK1476467T3 (da) IgG3-immunglobulin som beskyttelsesmarkör mod virusinfektionssygdomme og anvendelser deraf
TW200621799A (en) Acylated nonadepsipeptides II
ATE433459T1 (de) Desoxo-nonadepsipeptide
ECSP034872A (es) Nuevos heterociclos 3
ATE455789T1 (de) Substituierte nonadepsipeptide
PT1765370E (pt) Parapoxvirus em associação com outros agentes antivirais para o tratamento de hiv/sida
DE60231605D1 (de) Immunomodulator zur bekämpfung von durch humanen immunschwächevirus (hiv) vermittelte krankheiten/infektionen
DK1474415T3 (da) 1-phenyl-2-heteroaryl-substituerede benzimidazolderivater, deres anvendelse til fremstilling af lægemidler til behandling af immunologiske sygdomme
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases